Decreasing poly(ADP-ribose) polymerase activity restores δF508 CFTR trafficking

Frontiers in Pharmacology

Volumn 3 SEP, Issue , 2012, Pages

  Anjos, Suzana M ^a   Robert, Renaud ^b   Waller, Daniel ^a   Zhang, Dong Lei ^a   Balghi, Haouaria ^b   Sampson, Heidi M ^a   Ciciriello, Fabiana ^a   Lesimple, Pierre ^b   Carlile, Graeme W ^a   Goepp, Julie ^b   Liao, Jie ^b   Ferraro, Pasquale ^c   Phillipe, Romeo ^d   Dantzer, Françoise ^e   Hanrahan, John W ^b   Thomas, David Y ^a  

^a MCGILL UNIVERSITY   (Canada)

^b Department of Physiology   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d MONTREAL HEART INSTITUTE   (Canada)

^e UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

ABT 888; CF; Cystic fibrosis; DNA damage PARP 1 ; Oxidative stress; PARP 1

Indexed keywords

CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IODIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PEROXYNITRITE; SMALL INTERFERING RNA; VELIPARIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRONCHIAL EPITHELIAL CELL; CONTROLLED STUDY; CYSTIC FIBROSIS; EMBRYO; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME ASSAY; EPITHELIUM CELL; GENE DELETION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MOUSE; MUTANT; NONHUMAN; OXIDATIVE STRESS; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN HOMEOSTASIS; PROTEIN TRANSPORT; SALIVATION; WILD TYPE;

EID: 84867128775     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00165     Document Type: Article

References (42)

1. Abd Elmageed, Z. Y., Naura, A. S., Errami, Y., and Zerfaoui, M. (2011). The poly(ADP-ribose) polymerases (PARPs): new roles in intracellular transport. Cell Signal. 24, 1-8.
2. Andreone, T. L., O'Connor, M., Denenberg, A., Hake, P. W., and Zingarelli, B. (2003). Poly(ADPribose) polymerase-1 regulates activation of activator protein-1 in murine fibroblasts. J. Immunol. 170, 2113-2120.
3. Banasik, M., Komura, H., Shimoyama, M., and Ueda, K. (1992). Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADPribosyl)transferase. J. Biol. Chem. 267, 1569-1575.
4. Bartoszewski, R., Rab, A., Fu, L., Bartoszewska, S., Collawn, J., and Bebok, Z. (2011). CFTR expression regulation by the unfolded protein response. Meth. Enzymol. 491, 3-24.
5. Bartoszewski, R., Rab, A., Jurkuvenaite, A.,Mazur,M.,Wakefield,J.,Collawn, J. F.,and Bebok,Z. (2008).Activation of the unfolded protein response by deltaF508 CFTR. Am. J. Respir. Cell Mol. Biol. 39, 448-457.
6. Bebok, Z., Collawn, J. F., and Wakefield, J. (2005). Failure of cAMP agonists to activate rescued deltaF508 CFTR in CFBE41oairway epithelial monolayers. J. Physiol. 569, 601-615.
7. Bebok, Z., Varga, K., Hicks, J. K., Venglarik, C. J., Kovacs, T., Chen, L., Hardiman, K. M., Collawn J. F., Sorscher, E. J., and Matalon, S. (2002). Reactive oxygen nitrogen species decrease cystic fibrosis transmembrane conductance regulator expression and cAMP-mediated Clsecretion in airway epithelia. J. Biol. Chem. 277, 43041-43049.
8. Best, J. A., and Quinton, P. M. (2005). Salivary secretion assay for drug efficacy for cystic fibrosis in mice. Exp. Physiol. 90, 189-193.
9. Bobadilla, J. L., Macek, M. Jr., Fine, J. P., and Farrell, P. M. (2002). Cystic fibrosis: a worldwide analysis of CFTR mutations - correlation with incidence data and application to screening. Hum. Mutat. 19,575-606.
10. Brown, R. K., McBurney, A., Lunec, J., and Kelly, F. J. (1995). Oxidative damage to DNA in patients with cystic fibrosis. Free Radic. Biol. Med. 18, 801-806.
11. Brown, R. K., Wyatt, H., Price, J. F., and Kelly, F. J. (1996). Pulmonary dysfunction in cystic fibrosis is associatedwithoxidativestress.Eur.Respir. J. 9, 334-339.
12. Cantin, A. M., Bilodeau, G., Ouellet, C., Liao, J., and Hanrahan, J. W. (2006). Oxidant stress suppresses CFTR expression. Am. J. Physiol. Cell Physiol. 290, C262-C270.
13. Chen, J., Kinter, M., Shank, S., Cotton, C., Kelley, T. J., and Ziady, A. G. (2008). Dysfunction of Nrf-2 in CF epithelia leads to excess intracellular H2O2 and inflammatory cytokine production. PLoS ONE 3, e3367. doi:10.1371/journal.pone.0003367
14. Cheng, S. H., Gregory, R. J., Marshall, J., Paul, S., Souza, D. W., White, G. A., O'Riordan, C. R., and Smith, A. E. (1990). Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63, 827-834.
15. Collins, C. E., Quaggiotto, P., Wood, L., O'Loughlin, E. V., Henry, R. L., and Garg, M. L. (1999). Elevated plasma levels of F2 alpha isoprostane in cystic fibrosis. Lipids 34, 551-556.
16. Cuzzocrea, S. (2005). Shock, inflammation and PARP. Pharmacol. Res. 52, 72-82.
17. Donawho, C. K., Luo, Y., Penning, T. D., Bauch, J. L., Bouska, J. J., BontchevaDiaz, V. D., Cox, B. F., DeWeese, T. L., Dillehay, L. E., Ferguson, D. C., Ghoreishi-Haack, N. S., Grimm, D. R., Guan, R., Han, E. K., HolleyShanks, R. R., Hristov, B., Idler, K. B., Jarvis, K., Johnson, E. F., Kleinberg, L. R., Klinghofer, V., Lasko, L. M., Liu, X., Marsh, K. C., McGonigal, T. P., Meulbroek, J. A., Olson, A. M., Palma, J. P., Rodriguez, L. E., Shi, Y., Stavropoulos, J. A., Tsurutani, A. C., Zhu, G. D., Rosenberg, S. H., Giranda, V. L.,and Frost,D. J. (2007). ABT-888, an orally active poly(ADPribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res. 13, 2728-2737.
18. Ehrhardt, C., Collnot, E. M., Baldes, C., Becker, U., Laue, M., Kim, K. J., and Lehr, C. M. (2006). Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o. Cell Tissue Res. 323, 405-415.
19. French, P. J., Bijman, J., Bot, A. G., Boomaars, W. E., Scholte, B. J., and de Jonge, H. R. (1997). Genistein activates CFTR Clchannels via a tyrosine kinaseand protein phosphatase-independent mechanism. Am. J. Physiol. 273, C747-C753.
20. Fulcher, M. L., Gabriel, S., Burns, K. A., Yankaskas, J. R., and Randell, S. H. (2005). Well-differentiated human airway epithelial cell cultures. Meth- ods Mol. Med. 107, 183-206.
21. Gagne, J. P., Isabelle, M., Lo, K. S., Bourassa, S., Hendzel, M. J., Dawson, V. L., Dawson, T. M., and Poirier, G. G. (2008). Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes. Nucleic Acids Res. 36, 6959-6976.
22. Galli, F., Battistoni, A., Gambari, R., Pompella, A., Bragonzi, A., Pilolli, F., Iuliano, L., Piroddi, M., Dechecchi, M. C., and Cabrini, G. (2012). Oxidative stress and antioxidant therapy in cystic fibrosis. Biochim. Biophys. Acta 1822, 690-713.
23. Loo,T.W.,Bartlett,M. C.,and Clarke,D. M. (2005). Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound. Mol. Pharm. 2, 407-413.
24. Lukacs, G. L., Mohamed, A., Kartner, N., Chang, X. B., Riordan, J. R., and Grinstein, S. (1994). Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. EMBO J. 13, 6076-6086.
25. Luo, X., and Kraus, W. L. (2005). On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev. 26,417-432.
26. Maiuri, L., Raia, V., De Marco, G., Coletta, S., de Ritis, G., Londei, M., and Auricchio, S. (1997). DNA fragmentation is a feature of cystic fibrosis epithelial cells: a disease with inappropriate apoptosis? FEBS Lett. 408, 225-231.
27. McCarthy, V. A., and Harris, A. (2005). The CFTR gene and regulation of its expression. Pediatr. Pulmonol. 40, 1-8
28. Muscal, J. A., Thompson, P. A., Giranda, V. L., Dayton, B. D., Bauch, J., Horton, T., McGuffey, L., Nuchtern, J. G., Dauser, R. C., Gibson, B. W., Blaney, S. M., and Su, J. M. (2010). Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemother. Pharmacol. 65, 419-425.
29. Pacher, P., and Szabo, C. (2008). Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. Am. J. Pathol. 173, 2-13.
30. Pedemonte, N., Tomati, V., Sondo, E., and Galietta, L. J. (2010). Influence of cell background on pharmacological rescue of mutant CFTR. Am. J. Physiol. Cell Physiol. 298, C866- C874.
31. Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J. L., Drumm, M. L., Iannuzzi, M. C., Collins, F. S., Tsui, L.-C. (1989). Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066-1073.
32. Robert, R., Carlile, G. C., Liao, J., Balghi, H., Lesimple, P., Liu, N., Kus, B., Rotin, D., Wilke, M., de Jonge, H. R., Scholte, B. J., Thomas, D. Y., and Hanrahan, J. W. (2010). Correction of {Delta}F508-CFTR trafficking defect by the bioavailable compound glafenine. Mol. Pharmacol. 77, 922-923.
33. Robert, R., Carlile, G. W., Pavel, C., Liu, N., Anjos, S. M., Liao, J., Luo, Y., Zhang, D., Thomas, D. Y., and Hanrahan, J. W. (2008). Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol. Pharmacol. 73, 478-489.
34. Rottner, M., Freyssinet, J. M., and Martinez, M. C. (2009). Mechanisms of the noxious inflammatory cycle in cystic fibrosis. Respir. Res. 10, 23.
35. Roum, J. H., Buhl, R., McElvaney, N. G., Borok, Z., and Crystal, R. G. (1993). Systemic deficiency of glutathione in cystic fibrosis. J. Appl. Physiol. 75, 2419-2424.
36. Schreiber, V., Dantzer, F., Ame, J. C., and de Murcia, G. (2006). Poly(ADPribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 7, 517-528.
37. Szabo, C., Ischiropoulos, H., and Radi, R. (2007). Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat. Rev. Drug Discov. 6, 662-680.
38. van Doorninck, J. H., French, P. J., Verbeek, E., Peters, R. H., Morreau, H., Bijman, J., and Scholte, B. J. (1995). A mouse model for the cystic fibrosis delta F508 mutation. EMBO J. 14, 4403-4411.
39. Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., and McCartney, J. (2011). Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl. Acad. Sci. U.S.A. 108, 18843-18848.
40. Virag, L. (2005). Structure and function of poly(ADP-ribose) polymerase1: role in oxidative stress-related pathologies. Curr. Vasc. Pharmacol. 3, 209-214.
41. Wetmore, D. R., Joseloff, E., Pilewski, J., Lee, D. P., Lawton, K. A., Mitchell, M. W., Milburn, M. V., Ryals, J. A., and Guo, L. (2010). Metabolomic profiling reveals biochemical pathways and biomarkers associated with pathogenesis in cystic fibrosis cells. J. Biol. Chem. 285, 30516-30522.
42. Wible, B. A., Hawryluk, P., Ficker, E., Kuryshev, Y. A., Kirsch, G., and Brown, A. M. (2005). HERGLite: a novel comprehensive highthroughput screen for drug-induced hERG risk. J. Pharmacol. Toxicol. Methods 52, 136-145.